Domestic pharma sector posts 12 per cent growth in february 2016
The domestic pharma sector posted a growth of 12 per cent in February 2016 on the back of steady volumes, sustained healthy price hikes and new launches as per a report by Religare Institutional Research.
March 14, 2016: The pharmaceutical market research company AIOCD AWACS stated that volumes, prices and new launches contributed 3.7 per cent, 5.4 per cent and 3 per cent respectively to domestic market growth. The NLEM (National List of Essential Medicines) portfolio registered a growth of 6.9 per cent y-o-y, while the non-NLEM portfolio grew at 12.9 per cent.
The anti-diabetic, cardiac, derma and gastrointestinal segments which contribute about 40 per cent of the domestic pharma market outperformed the market growth by 4-6 per cent. On the other hand, respiratory and anti-infective segments’ growth fell to 5.8 per cent and 5.3 per cent in comparison to1 2.5 per cent and 8.1 per cent since April 2015. Both the segments account for 24 per cent of the market share.